A Phase 1 trial of intravenous boronophenylalanine-fructose complex in patients with glioblastoma multiforme
Conference
·
OSTI ID:390617
- Beth Israel Medical Center, New York, NY (United States)
- Brookhaven National Lab., Upton, NY (United States)
Boron neutron capture therapy (BNCT) of glioblastoma multiforme was initially performed at the Brookhaven National Laboratory in the early 1950`s While this treatment for malignant brain tumors has continued in Japan, new worldwide interest has been stimulated by the development of new and more selective boron compounds. Boronophenylalanine (BPA) is a blood-brain barrier penetrating compound that has been used in BNCT of malignant melanomas. SPA has been employed experimentally in BNCT of rat gliosarcoma and has potential use in the treatment of human glioblastoma. As a preface to clinical BNCT trials, we studied the biodistribution of SPA in patients with glioblastoma.
- Research Organization:
- Brookhaven National Lab., Upton, NY (United States)
- Sponsoring Organization:
- USDOE, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 390617
- Report Number(s):
- BNL--63412; CONF-9410281--7; ON: DE97000007
- Country of Publication:
- United States
- Language:
- English
Similar Records
Boron neutron capture therapy of glioblastoma multiforme using the p- boronophenylalanine-fructose complex and epithermal neutrons
Clinical trial of BNCT for glioblastoma multiforme
Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine
Conference
·
Fri Dec 30 23:00:00 EST 1994
·
OSTI ID:419224
Clinical trial of BNCT for glioblastoma multiforme
Journal Article
·
Mon Dec 30 23:00:00 EST 1996
· Transactions of the American Nuclear Society
·
OSTI ID:426308
Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine
Conference
·
Sun Dec 31 23:00:00 EST 1989
·
OSTI ID:5643007